🔎 Trials Near Me

Home › Acute Myeloid Leukemia › Ohio › Cincinnati

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Cincinnati, OH

Isang pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Cincinnati. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • Good Samaritan Hospital - Cincinnati, Cincinnati
  • Oncology Hematology Care Inc-Kenwood, Cincinnati
  • Bethesda North Hospital, Cincinnati
  • at 3 pa
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Nagre-recruitObservasyonal na pag-aaral
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 3
  • Oncology Hematology Care, Cincinnati
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Hanggang edad 21 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07012044

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Nagre-recruitPhase 3
  • Cincinnati Children's Hospital Medical Center, Cincinnati
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Nagre-recruitObservasyonal na pag-aaral
  • University of Cincinnati, Cincinnati
Edad 0 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Nagre-recruitPhase 3
  • US-Cincinnati OH-CINCY, Cincinnati
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 3
  • US-Cincinnati OH-CINCY, Cincinnati
Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Nagre-recruitPhase 1
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi ang layo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05886049

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06177067

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Nagre-recruitPhase 3
  • University of Cincinnati Medical Center (University Hospital), Cincinnati
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Nagre-recruitObservasyonal na pag-aaral
  • Cincinnati Children's Hospital, Cincinnati
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Nagre-recruitPhase 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
Edad 13 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT04771572

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Nagre-recruitPhase 1
  • Cincinnati Children's Hospital, Cincinnati
Hanggang edad 21 · Lahat ng kasarian · Na-update Abr 22, 2026 · NCT05101551

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 1/2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Edad 2 pataas · Lahat ng kasarian · Na-update Peb 25, 2026 · NCT05580601

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Nagre-recruitPhase 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Edad 1 hanggang 39 · Lahat ng kasarian · Na-update Peb 18, 2026 · NCT03826992

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Nagre-recruitPhase 2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
3 Months · Lahat ng kasarian · Na-update Nob 12, 2025 · NCT02143830

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Nagre-recruitPhase 1
  • Oncology Hematology Care, Cincinnati
Edad 18 pataas · Lahat ng kasarian · Na-update May 11, 2025 · NCT06634394

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Nagre-recruitPhase 1
  • University of Cincinnati, Cincinnati
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 15, 2024 · NCT06034275

Pag-aaral para sa Acute Myeloid Leukemia sa ibang lungsod

Iba pang pag-aaral sa Cincinnati

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.